Case Report: Immune checkpoint inhibitor-induced myositis without elevated creatine kinase
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancers like malignant melanoma. However, they can lead to a range of immune-related adverse events (irAEs), impacting various organ systems. Among these, myositis is a rare but serious irAE, typically characterized by...
Saved in:
Main Authors: | Klajdi Begaj, Raphael Wilhelm, Alisa Lepper, Maike Kaufhold, Jakob Veeser, Stephan Grabbe, Henner Stege |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1592385/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Incidence and Immunopathology of Myositis in Rectal Cancer Patients Treated With Neoadjuvant Immune Checkpoint Inhibitors and Chemoradiotherapy: Findings From the CHINOREC Trial
by: Rebecca Zirnbauer, et al.
Published: (2025-07-01) -
Myositis in Scrub Typhus: Atypical Presentation
by: Parth Sharma, et al.
Published: (2025-07-01) -
Can Janus kinase inhibitors be used to treat immune checkpoint inhibitor associated adverse events?
by: Jürgen Braun, et al.
Published: (2024-11-01) -
Overlap of myasthenia gravis, myocarditis, and inflammatory myopathy secondary to immune checkpoint inhibitor (pembrolizumab) on a background of previously undiagnosed thymoma-associated acetylcholine receptor antibody-positive myasthenia gravis
by: O. V. Finleyson
Published: (2025-04-01) -
Immunohistochemical Profiling of Immune Checkpoints in Chronic Hepatitis B Liver Tissue
by: João Panão-Costa, et al.
Published: (2025-06-01)